Mannitol Approved as Add-On Maintenance Therapy for Cystic Fibrosis
Bronchitol is only indicated for use in adults who have passed the Bronchitol Tolerance Test.
Obstructive Lung Disease
Ivacaftor May Be Effective for Infants With Cystic Fibrosis and Gating Mutation
Ivacaftor was safe and associated with improvements in cystic fibrosis transmembrane conductance regulator function in infants with CF and a gating mutation.
Increased GERD Risk in End-Stage Lung Disease Without Esophageal Disease
End-stage lung disease may significantly increase the risk for gastroesophageal reflux disease (GERD) in patients undergoing lung transplant without primary esophageal disease.
Intravenous vs Oral Antibiotics for P aeruginosa Treatment in Cystic Fibrosis
Intravenous antibiotics do not achieve greater sustained eradication of Pseudomonas aeruginosa in patients with cystic fibrosis compared with oral therapy.
Ivacaftor Approval Expanded to Include Younger Patients With Cystic Fibrosis
The approval was based on data from a phase 3 open-label safety study that included a cohort of 6 children 4 months to <6 months of age.
Cystic Fibrosis Outcomes With Concomitant Azithromycin and Tobramycin Use
Patients with cystic fibrosis who had pulmonary exacerbations treated with concomitant azithromycin and tobramycin had worse outcomes than those treated with tobramycin alone.
Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis
Age may influence outcomes in lung transplant recipients with cystic fibrosis.
CFHealthHub Criteria May Be Useful to Diagnose P Aeruginosa in Cystic Fibrosis
Preliminary evidence suggests that the CFHealthHub criteria are valid and useful in diagnosing chronic Pseudomonas aeruginosa in adults with cystic fibrosis.
Prolonged Heat Exposure in Cystic Fibrosis Can Lead to Metabolic Alkalosis
In patients with cystic fibrosis, prolonged exposure to heat can lead to chloride-deficient metabolic alkalosis as a result of a loss of electrolytes through sweat.
Brensocatib Receives Breakthrough Therapy Status for Non-CF Bronchiectasis
The FDA has granted Breakthrough Therapy designation to brensocatib for the treatment of adults with non-cystic fibrosis bronchiectasis for reducing exacerbations.
- Loading...
Loading...
Next post in Obstructive Lung Disease
Loading... 
Loading...